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Updates on the Diagnosis and Management of Hepatocellular 
Carcinoma
Aimun Raees1, Muhammad Kamran2, Hasan Özkan3  , Wasim Jafri4  
AbstrAct
Introduction: Globally, the incidence, as well as mortality, related to hepatocellular carcinoma (HCC) is on the rise, owing to relatively few 
curative options. Underlying cirrhosis is the most common etiology leading to HCC, but risk factors of cirrhosis show great regional variability. 
Over the years, there has been a steady development in the diagnostic and therapeutic modalities of HCC, including the availability of a wide 
range of systemic chemotherapeutic agents. We aim to review the recent advancements in the diagnostic and therapeutic strategies for HCC.
Methodology: The literature search was done using databases PubMed, Cochrane, and Science Direct, and the latest relevant articles were 
reviewed. 
Findings: Screening of HCC is a pivotal step in the early diagnosis of the disease. Current guidelines recommend using ultrasound and alfa 
fetoprotein but various new biomarkers are under active research that might aid in diagnosing very small tumors, not picked up by the current 
screening methods. Treatment options are decided based upon the overall performance of the patient and the extent of the disease, as per the 
Barcelona classification. There are very few options that offer a cure for the disease, ranging from liver resection and transplantation to tumor 
ablation. Downstaging has proven to have a significant role in the course of the disease. An attempt to control the disease can be made via 
radiological interventions, such as transarterial chemoembolization, transarterial radioembolization, or radiation therapy. For advanced disease, 
sorafenib used to be the only option until a couple of years ago. Recently, many other systemic agents have received approval as first-line and 
second-line therapies for HCC. Genomics is an area of active clinical research as understanding the mutations and genomics involved in the 
evolution of HCC might lead to a breakthrough therapy.
Keywords: Contrast-enhanced ultrasound, Genomics, Hepatocellular carcinoma, Immune checkpoint inhibitors, Lenvatinib, Metabolomics, 
Microwave ablation, Nivolumab, Transarterial radioembolization.
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IntroductIon
Hepatocellular carcinoma (HCC) is one of the most lethal cancers 
as its incidence has been on the rise for the past 10 years, making 
it the sixth most commonly diagnosed cancer worldwide and 
the fourth leading cause of cancer-related deaths annually.1 
In 2018, the total number of new HCC cases globally was 
approximately 670,000, with 625,000 HCC related deaths.2 It 
is the most common primary liver neoplasm with cirrhosis 
being the main underlying etiology. The risk factors of cirrhosis 
are significantly variable. Chronic hepatitis B virus (HBV) and 
aflatoxin exposure are common risk factors for cirrhosis in Asia 
and Africa3 whereas in developed countries like USA, Europe, 
and Japan, chronic hepatitis C virus (HCV) along with alcoholic 
and nonalcoholic liver disease are more frequently identified.4,5 
The only effective way to reduce the risk of HCC is to promote a 
healthy lifestyle along with adhering to the treatment of chronic 
hepatitis.6 Additionally, vaccination against HBV is another 
crucial step towards eliminating the risk of development of 
HCC. HCC is considered to have a poor prognosis because most 
cases are usually subclinical at the early stages when potentially 
curative treatment options are available and by the time of 
detection, they have reached to an advanced stage with very 
limited options of treatment remaining. This review article 
aims to analyze the recent advancements in the diagnosis and 
treatment of HCC and the available evidence to support the new 
therapeutic modalities.
Methods
PubMed, Cochrane, and Science Direct databases were searched 
using keywords HCC, liver-directed therapies, systemic therapy, and 
immunotherapy. Relevant information from peer-reviewed articles 
was included. Appropriate reference articles were also retrieved. 
Non-English articles and non-human studies were excluded. 
Diagnosis
The aim of surveillance programs is to detect early tumors in patients 
with a good prognosis profile. This reduces cancer-related morbidity 
and mortality and increases survival rate, as curative treatments can 
be readily offered at this point in time. Surveillance is recommended 
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In 2011, a standardized system was first proposed for the 
interpretation and reporting of liver lesions. This system, endorsed 
by the American College of Radiology, is called Liver Image 
Reporting and Data System (LI-RADS) which classifies liver lesions 
into five categories based on contrast uptake and washout. It ranges 
from LR-1 lesions that are definitely benign, to LR-5 lesions that are 
conclusive of HCC. LI-RADS can be applied on CT, MRI, or CEUS. The 
system was recently updated in 2018.37 LI-RADS is also utilized for 
the assessment and reporting of tumor response after treatment.
Quite often, atypical lesions are encountered that do not 
exhibit specific vascular profile and thus cannot be characterized 
via LI-RADS system. It is also essential to note that LI-RADS cannot 
be applied if the liver is noncirrhotic.38 In both of these cases, 
a diagnostic biopsy becomes necessary. A false-negative rate of 
biopsies is around 30% due to the poor yield of the sample; hence, 
a negative biopsy is not adequate to rule out HCC.39 A group of 
immunohistochemical stains including glutamine synthetase, 
glypican-3, and heat shock protein40 should be requested as 
it increases specificity to 100% while sensitivity may still be 
suboptimal.41,39
Metabolomics is an evolving technology that involves 
a detailed examination of metabolites in a biological sample, also 
analyzing at the same time the variations in the metabolic profile 
as a result of exposure to the disease or drug.42 There is growing 
interest in the role of metabolomics in predicting early HCC, and 
metabolomics studies have been carried out in common liver 
disorders like alcoholic liver disease, cirrhosis, and nonalcoholic 
fatty liver disease.43 It is expected that such studies may be useful 
in decreasing the occurrence of HCC in at-risk population.
Staging
Prognostication of disease is critical before planning therapeutic 
strategies for HCC. For this purpose, several staging systems 
have been designed.44 The Barcelona Clinic Liver Cancer (BCLC) 
system has been the most widely recognized and extensively 
validated classification since its first publication in 1999.45,46 
It incorporates tumor burden, degree of liver dysfunction, and 
patient’s performance status based on the Eastern Cooperative 
Oncology Group (ECOG) for determination of cancer stage and 
patient prognosis. It classifies patients into five stages starting from 
0 (very early), A (early), B (intermediate), C (advanced) to D (terminal) 
stage.47 Both EASL and AASLD recommend using the BCLC system 
for HCC staging and prognostic assessment. Table 1 shows the latest 
version of the BCLC staging system. 
in all patients with cirrhosis irrespective of etiology. However, patients 
having chronic HBV in the absence of underlying cirrhosis also require 
regular surveillance, since HBV is an independent risk factor for HCC 
with a yearly incidence of more than 0.2%.7 The average tumor 
doubling time is 4 to 6 months; hence, most of the clinical guidelines 
suggest 6  monthly surveillance in patients with cirrhosis.8-10 
Tumor markers add value to surveillance as they are non-invasive 
yet objective evaluation tools. The recommended investigation 
for surveillance is ultrasonography with or without serum alpha-
fetoprotein (AFP) levels, as combination of the two modalities 
amplifies the rate of detection of early HCC. Ultrasonography is widely 
available, easily tolerated, and cost-effective with a sensitivity of 58 to 
80% when performed by an expert.11-14 Having said that, AFP is only 
80% specific in diagnosing HCC, and the operator and equipment 
dependence of ultrasonography may raise false suspicions and add 
to the overall cost.15 Moreover, AFP can be normal in about 40% of 
patients with early disease16 while sensitivity of ultrasonography 
falls to only 30% for tumors <2 cm tumors.17 This lead to the search 
of other tumor markers such as lectin-bound alpha-fetoprotein 
(AFP-L3), glypican 3, des-gamma carboxyprothrombin (DCP), 
osteopontin, annexin A2, acylcarnitine, alpha-fucosidase, Dickkopf 
1, and Golgi protein 73. These have been studied and proven to be 
useful but none of these were superior in accuracy when compared 
to AFP.18,19 According to a study, more than 35% of patients with 
very early HCC have elevated levels of DCP,20 while another study 
claims that combination of DCP with AFP significantly improves the 
detection rate of HCC. The specificity of the DCP is 91% in contrast 
to 70% for AFP; however, sensitivity is significantly low (41%).21 
AFP-L3 has been found to be remarkably specific for HCC and is 
associated with more aggressive and infiltrative tumors.22 A recent 
meta-analysis showed moderate accuracy of Dickkopf-1 for detecting 
HCC.23 Abnormally expressed circular RNAs are novel biomarkers 
being studied for detection of early HCC.24 A panel of seven micro-
RNAs has shown high diagnostic accuracy in HBV-related HCC.25,26 
A study done in Egypt demonstrated vascular endothelial growth 
factor (VEGF) as a promising serum marker for HCC.27 Besides 
biochemical markers, a serological model called GALAD score has 
also been introduced, which uses age, sex, and tumor markers for the 
diagnosis of HCC. It has emerged as a beneficial tool in a few studies 
but has not been externally validated so far.28
HCC is only cancer that requires only imaging to reach 
a definitive diagnosis. Almost all guidelines recommend an 
image-based diagnosis of HCC. On a background of liver cirrhosis, 
a definite diagnosis of HCC can be made if characteristic features 
such as arterial phase hyperenhancement while washout during 
delayed venous phase is present in a triphasic imaging study.29,30 
Either a contrast-enhanced computed tomography (CT) scan or 
magnetic resonance imaging (MRI) can be done, as both have similar 
diagnostic accuracy. The sensitivity and specificity of triphasic CT 
scan are 81 and 93%, respectively, while that of MRI is 91 and 95%, 
respectively.31 Use of hepatobiliary contrast agents (gadoxetic 
acid and gadobenate dimeglumine) in MRI can further enhance 
sensitivity, but specificity may be lower than extracellular contrast 
agents for small HCC.32,33 A major limitation of CT scan is the intense 
exposure to radiation. Besides CT and MRI, contrast-enhanced 
ultrasound (CEUS) has also proven to be highly sensitive for the 
diagnosis of HCC.34,35 A recent multicenter prospective study and 
a meta-analysis, both report excellent diagnostic accuracy and high 
specificity of CEUS for the diagnosis of HCC.36 However, CEUS may be 
unable to distinguish intrahepatic cholangiocarcinoma from HCC. 
Table 1: The Barcelona Clinic Liver Cancer (BCLC) system for staging 
of HCC
Stage Tumor burden




0 (very early) Single lesion 
<2 cm Child-Pugh A
0A (early) Single or three lesions <3 cm
Child-Pugh A or B
B (intermediate) Multinodular 
tumor




D (terminal) Extensive disease Child-Pugh C 3–4
Updates on the Diagnosis and Management of Hepatocellular Carcinoma
Euroasian Journal of Hepato-Gastroenterology, Volume 11 Issue 1 (January–June 2021)34
Treatment
While opting for therapeutic strategies, the main intention is 
to improve quality of life. The modality of treatment is chosen 
according to the clinical status of the patient based on the 
BCLC system. HCC is a complex disease with diverse therapeutic 
options available; hence, it is advised to refer HCC patients to 
multidisciplinary care teams that include hepatologists, surgeons, 
interventional radiologists, and oncologists to develop an effective 
treatment strategy. 
Curative Therapy
For patients with BCLC stage 0 to A, curative treatments can be 
offered. Potential curative options include liver resection (LR), 
liver transplant (LT), and ablation. Ablation can be done through 
radiofrequency waves (RFA), microwave (MWA), cryotherapy, or 
alcohol injection.
Liver Resection
In patients with very early stage HCC without portal hypertension 
or high bilirubin, LR is the treatment of choice. Decompensated 
cirrhosis and vascular invasion are contraindications to LR. The 
proportion of patients who fulfill the criteria for resection is usually 
5 to 10%. Potential complications can be liver failure, infection, 
thrombosis, or bleeding. The rate of survival depends upon the 
operator experience and disease status at the time of surgery, 
but the 5-year overall survival (OS) is estimated to be around 25 
to 69.5%.48,49 The main demerit is a high recurrence rate of HCC, 
approximately 60 to 100%.50 No adjuvant or neoadjuvant therapies 
have been approved yet to decrease the risk of recurrence after 
resection. Laparoscopic surgery is a less invasive alternative to open 
resection, with reduced chances of postprocedure complications 
and similar outcomes as open surgery51,52 but trials are needed for 
its validation. A randomized control trial that compared open LR 
with laparoscopic surgery concluded that the laparoscopic method 
was superior to open surgery in terms of safety with equivocal 
oncological outcome.53 According to a recent meta-analysis, 
laparoscopic LR provides comparable survival rates as conventional 
open approach.54
Liver Transplantation
Liver transplantation provides the best outcome to cirrhotic patients 
with early HCC. Besides removing tumor tissue, it also has the added 
benefit of simultaneously curing cirrhosis. As per EASL and AASLD 
guidelines, patients are selected based upon Milan’s criteria that 
includes HCC <5 cm or three nodules less than 3 cm each with no 
microvascular invasion on imaging.55 The result of LT is dependent 
on various factors such as tumor burden, ischemia time during 
surgery, and use of immunosuppressive drugs.56,57 Shortage of 
organ availability is the main limiting factor resulting in candidates 
being dropped out from the waiting list. Although associated with 
higher postoperative morbidity and early mortality, LT delivers an 
excellent 5-year OS rate of >70%.58-60 The recurrence rates are low, 
approximately 10 to 18%.61,62 The practice of liver transplantation 
continues to evolve with the promotion of live organ donation.
Ablation
Patients with stage 0-A disease, unsuitable for surgery due 
to elevated portal pressure, anatomic location of tumor, or 
comorbidities, should undergo ablation. Ablation is a minimally 
invasive approach that may use RFA, MWA, alcohol, laser, or 
cryotherapy. The basic underlying mechanism is alteration of 
temperature leading to tumor necrosis. RFA is considered the 
first line therapy63 and is recommended by both EASL and APASL. 
Complications may be intra-abdominal hemorrhage, liver failure, 
infection, tumor seeding, or biliary tract injury.64 It is a very safe 
procedure with <0.5% mortality.65 Limitations include location of 
tumor close to vessels, gallbladder, stomach, colon, or any other 
viscera.66 The 5-year OS and recurrence rates of RFA are very similar 
to that of LR.67
Microwave ablation (MWA) is a novel approach that has shown 
outstanding results in the management of HCC. It offers similar 
advantages as that of RFA as well as several other benefits like higher 
degree of tumor necrosis, ability to treat larger tumors, reduced 
procedure time, and feasibility to perform in tumors located close 
to viscera or biliary tree.68 According to the available literature, there 
is no statistically significant difference in efficacy and complication 
rates between MWA and RFA.69-71 A recent RCT also endorsed 
non-inferiority of MWA in terms of safety and local recurrence.72
Noncurative Therapy
For patients who are not eligible for curative treatments, several 
other therapies are advocated to decrease tumor burden and 
to prolong long-term survival. These include both palliative 
interventions and systemic therapies.
Locoregional Therapy
Transarterial Chemoembolization
The vascular supply of HCC is derived from the hepatic artery, while 
the rest of the liver parenchyma is supplied mainly by the portal 
vein. This difference in vascular supply is the basic principle of 
all embolization therapies as devascularization of tumor tissue is 
acquired without affecting normal tissue. This is achieved via drugs, 
embolic, or radioactive particles.73 Guidelines have recommended 
transarterial chemoembolization (TACE) as the standard option for 
patients with HCC of BCLC stage B as it has shown great survival 
benefit.74-76
Conventional-TACE (cTACE) uses injection of chemotherapeutic 
agents, such as doxorubicin, cisplatin, or mitomycin, mixed with 
lipoidol into hepatic artery and completely obstructing it with 
gelatin sponge, thus inducing ischemia and cytotoxicity leading 
to tumor necrosis.77 Patients with portal vein thrombosis or 
extrahepatic disease, high localized tumor burden (>10  cm), or 
eGFR <30  mL/minute are not considered good candidates for 
the procedure.73-79 Postembolization syndrome is a frequently 
occurring complication, characterized by fever, abdominal pain, 
nausea, and vomiting. It is usually mild and responds well to 
antipyretic and analgesic therapy.80
TACE with drug-eluting beads (DEB-TACE) is a modified 
version of conventional TACE in which polyvinyl alcohol hydrogel 
is used to seal off the artery. This causes a sustained release of 
chemotherapeutic drugs thus increasing cytotoxicity to tumor 
cells while reducing exposure to rest of the hepatic parenchyma 
and circulatory system.81,82 It is a better-tolerated procedure with 
improved results and less severe adverse events eventhough the 
rate of complications remains same as cTACE. The 5-year OS is 
reported to be 18 to 28.7 months with cTACE and 30 to 40 months 
with DEB-TACE.76,83 DEB-TACE is not considered superior 
to cTACE.84 
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SBRT include location of tumor near important organs like biliary 
tree or gastrointestinal tract increasing the risk of radiation induced 
inflammation and bleeding. Radiation induced liver disease, defined 
as hepatomegaly, ascites, and cholestasis, is a known complication 
of SBRT which can be fatal in 5 to 13% cases.96,97 According to a 
recent meta-analysis and a phase 2 clinical trial, the local control of 
HCC achieved by SBRT is equivalent to that of RFA.98,99 Studies have 
exhibited a median overall survival of 8 to 17 months after SBRT.100 
However, there is still a paucity of data on long term survival beyond 
2 years. No progression of disease was seen upto 1 to 3 years in 87 
to 100% of cases.101
Systemic Therapy
Systemic therapy is the cornerstone of treatment for patients with 
advanced disease who are not surgical candidates or fit for liver 
directed therapies. Over the past couple of years, systemic therapy 
has immensely evolved, with multiple new drugs being approved 
while others are under evaluation. Figure 1 shows currently available 
drugs for systemic therapy.
Multikinase Inhibitors
These drugs exert antiproliferative, antiangiogenic and apoptotic 
properties by blocking RAF signaling along with VEGF, platelet 
growth factor and KIT.
First-line Therapy
Sorafenib
Sorafenib remained the only standard of care for patients with 
BCLC-C disease, since its approval in 2007. Although it was first 
discovered in 1990 but only gained FDA approval after the phase 
3 sorafenib HCC assessment randomized protocol trial that proved 
an increase in OS when compared with placebo (median OS 10.7 
vs 7.9 months, respectively) in patients with advanced HCC.102 The 
trial also indicated that sorafenib was potentially effective against 
HCC regardless of tumor burden, ECOG class, liver status, AFP 
levels, or previous therapy.103,104 The reported time to radiologic 
progression was 5.5  months with sorafenib vs 2.8  months with 
placebo. However, the overall response rate (ORR) was low. 
Commonly encountered side effects were diarrhea, weight loss, 
arterial hypertension, fatigue, and hand-foot syndrome. Around 
30% patients do not tolerate sorafenib due to the side effects. 
Improved outcomes were observed in patients who developed 
dermatological side effects.105
TACE with degradable starch microspheres (DSM-TACE) is a 
novel technique that uses a completely degradable, hydrophilic 
starch matrix that is able to reach at arteriolar or capillary level due 
to its small diameter causing transient occlusion of small arteries. 
This limited-time occlusion reduces the chances of systemic toxicity 
and postembolization syndrome.85 Some studies have shown its 
potential safety and efficacy proposing it as a second-line liver-
directed therapy for patients with intermediate- to advanced-stage 
HCC.86,87 A prospective study showed a median OS of 36 months 
after DSM-TACE but randomized control trials are needed to validate 
these results.
Transarterial Radioembolization
Transarterial radioembolization (TARE), a form of selective internal 
radiation therapy, is a highly advanced liver-directed therapy, that 
uses intra-arterial injection of radioactive spheres (loaded with 
Yttrium-90, iodine-131, or rhenium-188) to cause radiation-induced 
tumor necrosis.88 The magnitude of ischemia is comparatively 
lesser in comparison to TACE, hence decreasing the chances and 
severity of postembolization syndrome. It is indicated for BCLC-B 
disease and unlike other radiological procedures, this intervention 
can also be done in patients with portal vein thrombosis or high 
tumor burden (bilobar disease). Patients not amenable to TARE 
are the ones with metastatic HCC, decompensated cirrhosis, 
prior radiation to liver, and significant hepatoenteric and 
hepatopulmonary shunts (>20%).89 Postprocedure complications 
include liver failure, radiation pneumonitis, biliary complications, 
radioembolization induced liver disease, and postembolization 
syndrome.90 The survival benefit is not reported to be very different 
from TACE ranging from 14 to 16.9 months, but TARE demonstrated 
reduced toxicity and longer time to progression of disease (13.3 vs 
8.4 months).91,92
Stereotactic Body Radiation
Historically, radiation therapy has never been a part of treatment 
algorithms in HCC. However, enormous technological developments 
over the last few decades have led to the introduction of stereotactic 
body radiation therapy (SBRT) as a promising treatment for HCC. 
It has been added to the NCCN guidelines for the treatment of 
patients with nonresectable tumors with portal vein thrombosis 
or extrahepatic metastases.93 A recent clinical audit showed 
excellent results of SBRT in terms of safety and efficacy for large 
inoperable HCCs.94 It has also shown great benefits in palliation of 
symptomatic patients with metastatic lesions.95 The limitations to 
Fig. 1: Systemic therapy for HCC
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Lenvatinib
Lenvatinib is another oral tyrosine kinase inhibitor that acts on 
VEGFR 1 to 3, FGFR 1-4. RET, KIT, and PDGFR alpha. Its ability to inhibit 
fibroblast growth factor receptors distinguishes it from sorafenib. 
Lenvatinib gained approval as first-line therapy for advanced HCC 
in 2018 on the basis of phase 3 REFLECT trial. The study included 
unresectable HCC, BCLC-B and C patients with no prior systemic 
therapy, and patients with greater than 50% liver impairment 
and portal or biliary invasion were excluded. The results affirmed 
non-inferiority of lenvatinib to sorafenib in terms of median OS 
(13.6 vs 12.3 months, respectively). Lenvatinib also demonstrated 
longer progression-free survival (7.3 vs 3.6 months), time for tumor 
progression (7.4 vs 3.7  months), and higher objective response 
rate (18.8 vs 6.5%) as well as better outcome in patients with AFP 
greater than 200 ng/mL. Adverse event profile was similar to that 
of sorafenib.106
Donafenib
Donafenib is a novel multikinase inhibitor that has revealed great 
anti-tumor activity and favorable tolerability. An open label, 
randomized, phase 2/3 clinical trial from China demonstrated 
significantly longer OS with donafenib compared to sorafenib 
(12.1 vs 10.2 months, respectively). Frequent adverse events with 
donafenib were hand-foot skin reaction, deranged liver functions, 
thrombocytopenia, and diarrhea.107 Donafenib is currently pending 
approval by the FDA. 
Second-line Therapy
Regorafenib
Regorafenib was the first drug that showed survival benefit as 
second-line treatment and was approved by FDA in 2017, after 
the results of a phase 3 trial (RESOURCE) which showed significant 
improvement in OS 10.6 vs 7.8 months with placebo, for patients 
who had disease progression on sorafenib. It is also a multikinase 
inhibitor with more profound antiangiogenic activity as it blocks 
both VEGF and TIE pathways. Mostly encountered side effects were 
hypertension, diarrhea, fatigue, and hand-foot reaction.108
Cabozantinib
Cabozantinib is a multikinase inhibitor that has stronger activity 
against MET and AXL signaling pathways. The approval of 
cabozantinib was based on a phase 3 trial (CELESTIAL) that 
evaluated its efficacy in patients who progressed on or did not 
tolerate sorafenib. The study demonstrated improved median OS 
(10.2 vs 8.0 months), progression-free survival (5.2 vs 1.9 months), 
and objective response rate (4 vs 1%). Adverse events commonly 




Ramucirumab is a monoclonal recombinant IgG1 antibody 
against VEGFR-2. A phase 3 study REACH-2 examined its action in 
patients with advanced HCC with AFP levels greater than 400 ng/
mL. The results were improved median OS (8.5 vs 7.3 months), 
progression-free survival (2.8 vs 1.6  months), and objective 
response rate (5 vs 1%).110 Ramucirumab received FDA approval 
as second-line agent against advanced HCC in May 2020.
Bevacizumab
It has recently been approved by FDA to be utilized as a combination 
drug with atezolizumab against advanced HCC.
Immunotherapy
Immunotherapy consists of immune checkpoint inhibitors that 
have the potential to target checkpoint proteins on immune 
and cancer cells. It is broadly classified, according to their target 
immune cells, into three types, programmed cell death protein-1 
(PD-1), programmed cell death 1 ligand 1 (PDL-1), and cytotoxic 
T-lymphocyte associated protein 4 (CTLA-4) antibodies.
Nivolumab
Nivolumab is a monoclonal antibody that blocks PD1-receptor. It 
gained accelerated approval as second-line therapy in 2017 based 
on a phase 2 study (CheckMate 040). Later, the phase 3 study 
(CheckMate 459) demonstrated the efficacy and safety of nivolumab 
in patients with advanced HCC who failed sorafenib therapy. 
According to the trial, the median OS was 16.4 vs 14.7  months 
with placebo, progression-free survival was 3.7 vs 3.8 months, and 
ORR was 20%. Fewer adverse effects were encountered compared 
to sorafenib which included rash, elevated liver and pancreatic 
enzymes, and pruritis.111
Pembrolizumab
On the basis of a phase 2 clinical trial, KEYNOTE-224, pembrolizumab 
received accelerated FDA approval in 2018. The study compared 
pembrolizumab with best supportive care in patients who 
developed progression on sorafenib and demonstrated improved 
median OS of 12.9 vs 10.6 months in the control group, progression-
free survival 4.9 vs 2.0 months, and ORR of 17%. Side effects were 
similar to that of nivolumab and tolerated well.
Combination Therapy
The IMbrave150 is considered a breakthrough study as it leads to the 
approval of the first combination therapy for HCC, simultaneously 
paving the way for further advancements in this field giving a ray 
of hope to the patients of HCC. Combination therapy is a field of 
continuous medical expansion, multiple trials using different drug 
combinations are ongoing and their outcomes are intently awaited.
Atezolizumab + Bevacizumab
This combination was approved in May 2020 as the first-line therapy 
against advanced HCC, bringing a revolution to HCC therapy with 
the idea that synergistic anti-tumor activity exerted by two drugs 
can be superior to single-drug therapy. The study (IMbrave150) 
compared combination of atezolizumab (PDL-1 inhibitor) and 
bevacizumab (anti-VEGF antibody) with sorafenib in patients with 
locally advanced or metastatic HCC. Results of the trial showed 
progression-free survival of 6.8 vs 4.3 months with sorafenib and 
ORR of 27.3 vs 11.9%, respectively. Commonly reported adverse 
effects with the combination are hypertension, hepatitis, fever, 
and proteinuria.112
Nivolumab + Ipilimumab
Nivolumab is a PD-1 inhibitor and ipilimumab is a CTLA-4 inhibitor 
and their combination gained accelerated approval in 2020. The 
trial CheckMate 040 reported an ORR of 31% and 24 months OS 
rate was 40%. Adverse events included fatigue, diarrhea, rash, 
pruritis, dyspnea, weight loss, abdominal pain, headache, arthralgia, 
vomiting, and musculoskeletal pain.113
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Other Potential Combination Therapies
The concept of combination therapies is rapidly accelerating 
as agents from different groups are being investigated for their 
potential activity against HCC. LEAP-002 is studying the effects of 
lenvatinib and pembrolizumab in advanced HCC.114 Combination 
therapy with durvalumab and tremelimumab is also underway.115 
Provisional results from a phase 2 study of camrelizumab plus 
FOLFOX look promising.116 The possibilities are endless, hence 
a good number of combination therapies are undergoing trials 
currently (Table 2). 
Genomic Therapy
The paucity of treatment options for HCC patients has stimulated 
the researchers to look into all possibilities that can potentially 
provide beneficial results. Genetic mutations associated with HCC 
are currently being studied in depth with the idea of targeting 
these specific mutations.117 Epigenetic alterations induced by 
DNA methylation seem to be reversible, thus presenting a possible 
target against which therapeutic strategies can be developed. DNA 
methylation inhibitors, azacytidine, and decitabine are currently 
being studied for HCC. A phase 1/2 trial conducted on decitabine 
showed favorable results.118 A phase 2 trial using a combination 
of guadecitabine, sorafenib, and oxaliplatin is currently ongoing 
(NCT03257761).119
The dysregulation of histones is also under active investigation, 
and drugs to modify their course are underway. Histone deacetylase 
inhibitors, such as belinostat and resminostat, are under trial. 
(NCT00321594, NCT00943449 ) Needless to say, it is only the tip of 
the iceberg and provides a future landscape in the treatment of 
HCC. It is expected that advancements in this field could lead to 
the development of revolutionary therapies with the best possible 
outcomes.
conclusIon
HCC is a universal health burden due to the rapidly rising mortality 
rate associated with it. According to the latest numbers, it is 
estimated that its incidence will continue to grow. It is crucial to 
devise therapeutic strategies that could control the disease and 
prolong the survival of patients. Fortunately, systemic therapy has 
advanced rapidly over the past few years. However, the advent 
of immunotherapy has proven to be a game changer. The role of 
genomic and adoptive cell therapy is still unclear. A lot of in-depth 
research is therefore needed to further enhance our perception of 
the disease at molecular and genetic levels, in order to explore new 
treatment options for HCC.
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